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Abstract
Background: Malaria remains a major public health problem in developing countries. Then in these countries
prompt access to effective antimalarial treatment such as Artemisinin based-Combination Therapies (ACT) proves to
be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is
being implemented. In this context it has become relevant to monitor ACT efficacy and provide recommendations
for the Senegalese national malaria control program.
Methods: An open randomized trial was conducted during two malaria transmission seasons (2011 and 2012) to
assess the efficacy and safety of three combinations: dihydro-artemisinin-piperaquine (DHAPQ), artemether-
lumefantrine (AL) and artesunate-amodiaquine (ASAQ). The primary end point of the study was represented by a
PCR adjusted adequate clinical and parasitological response (ACPR) at day 28. Secondary end points included: (i) a
ACPR at days 35 and 42, (ii) a parasite and fever clearance time, (iii) ACTs safety and tolerability. The 2003 WHO’s
protocol for antimalarial drug evaluation was used to assess each outcome.
Results: Overall, 534 patients were randomized selected to receive, either ASAQ (n = 180), AL (n = 178) or DHAPQ
(n = 176). The PCR adjusted ACPR at day 28 was 99.41% for the group ASAQ, while that was 100% in the AL and
DHAPQ groups (p = 0.37). The therapeutic efficacy was evaluated at 99.37% in the ASAQ arm versus 100% in AL
and DHAPQ arm at day 35 (p = 0.37). At day 42, the ACPR was 99.27% in the ASAQ group versus 100% for both AL
and DHAPQ groups, (p = 0.36). No serious adverse event was noted during the study period. Also a similar safety
profile was noted in the 3 study groups.
Conclusion: In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe
antimalarial drugs. However, it’s remains important to continue to monitor their efficacy.
Trial registration: PACTR 201305000552290.
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Background
Despite increasing efforts to control malaria, the disease
is still a public health problem. According to the World
Health Organization (WHO), there are 216 million new
malaria infection cases per year in the world. Also, the
disease causes 655 000 deaths per year in the world.
More than 81% of the new infection cases and 90% of
the deaths occur in Africa mainly in children under five
years [1]. The emergence and spread of the P. falcip-
arum resistance to the monotherapies such as chloro-
quine, sulfadoxine, pyrimethamine, has been a major
obstacle for malaria control in sub-saharan countries.
Then to deal with these resistance issues, the WHO
recommended Artemisinin based-Combination Therap-
ies (ACT) for the management of uncomplicated malaria
cases [2]. ACTs reduce malaria related morbidity and
mortality and the transmission of Plasmodium falcip-
arum by acting on gametocytes and reducing the
chances of development of drug resistance [3-5].
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In Senegal, the National Malaria Control Program
(NMCP) initiated in 2006 a nationwide scaling up
program of ACT [5]. Several ACTs are currently being
used in Senegal including Artemether-lumefantrine (AL)
and Artesunate-Amodiaquine (ASAQ) as first line treat-
ment and dihydro-artemisinin-piperaquine DHAPQ
(Duocotexcin*) as second line treatment [6].
Recent studies demonstrated a decline in ACTs
efficacy as well as artesunate monotherapy in the Asian
region [7,8]. This raised to some concerns related to
ACT efficacy in the context of scaling up antimalarial
intervention in West African countries particularly in
Senegal. Then it becomes relevant to monitor ACT
efficacy in Senegal.
In Senegal, notification of adverse events has been a
great challenge for the National Malaria Control
Programme although a pharmacovigilance system for
monitoring ACT drug related adverse events has been
established for several years [9]. Thus there is a need to
document the safety profile of commonly used ACTs in
Senegal when scaling up these antimalarial drugs. This
study was undertaken to assess the efficacy and safety of
three artemisinin combinations therapies for the treat-
ment of uncomplicated Plasmodium falciparum malaria
in Senegal.
Methods
Study period and area
The study was carried out during two malaria transmis-
sion seasons in two health centers: (i) Deggo which is
located 20 km form Dakar, the capital city and (ii) Keur
Soce located 200 km of South from Dakar. In the areas
around the health posts, malaria is highly seasonal
during the rainy season (July to October) with a peak of
transmission from September to December. Plasmodium
falciparum is the predominant species and transmission
is mainly due to Anopheles gambiae s.l. The enrollment
of patients started in 2011 and was completed in 2012.
Study design
The study was designed as an open randomized trial com-
paring three ACTs for the treatment of uncomplicated
Plasmodium falciparum malaria: Artesunate-Amodiaquine
(ASAQ), Artemether-Lumefantrine (AL) and Dihydroarte-
misinin-Piperaquine (DHAPQ). Randomization was per-
muted in blocks of 9. The primary endpoint was the PCR
adjusted adequate clinical and parasitological response
(ACPR) at day 28. Secondary end points included: (i) PCR
adjusted ACPR at day-35 and day-42, (ii) the parasite
clearance time, (iii) the fever clearance time and (iv) ACT
tolerability and safety.
The study was conducted as part of a national surveil-
lance program aimed at monitoring ACTs efficacy under
routine conditions.
Study population
Subjects were enrolled if their age was above 6 months
and they presented with uncomplicated Plasmodium
falciparum malaria with parasite density ranged from
1000 to 100,000 trophozoites/μl. Ability to take oral
medication and written informed consent were required
as part of the inclusion criteria. Patients presenting with
mono-infection by another species or mixed infectation,
severe vomiting, severe malnutrition, severe signs of
malaria (such as severe anemia, convulsion, respiratory
distress), a positive pregnancy test and patients who had
a history of allergy to study drugs or did not given
informed consent were excluded from the study.
Antimalarial treatment
After inclusion, all patients were weighed and random-
ized to receive one of three study drugs for three days.
The drugs were administered under the direct supervi-
sion of the medical staff. In case of vomiting within the
30 minutes following the first administration, the same
dose was administrated again.
Participants who vomited a second time were excluded
from the study and received intravenous quinine treat-
ment in accordance with the national malaria control
program guidelines (25 mg/kg/day for seven days 3 times
daily). The dosages of the study drugs were as follows:
Artesunate-Amodiaquine (ASAQ): the tablet con-
tains 4 mg/kg/day Artesunate (AS) plus 10 mg/kg/day
Amodiaquine (AQ). The drug was given once a day.
The dosage was adjusted according to the weight: one
tablet per day containing 25 mg/67.5 mg (4.5 - 9 kg),
one tablet per day containing 50 mg/135 mg (9 - 18 kg),
one tablet per day containing 100 mg/270 mg (18 - 36 kg)
and two tablets per day containing 100 mg/270 mg if
weight was more than 36 kg.
Artemether-Lumefantrine (AL): the drug was not
given with additional fat. The tablet contains 20 mg of
Artemether plus 120 mg of Lumefantrine. The drug was
given 2 times a day. The dosage was adjusted according
to the weight: two tablets per day (5 – 14 kg); four tab-
lets per day (15 – 24 kg); six tablets per day (25 – 45 kg)
and eight tablets per day if weight was more than 45 kg.
Dihydroartemisinin-Piperaquine (DHAPQ): the tablet
contains 40 mg of Dihydroartemisinin (DHA) plus
320 mg of Piperaquine (PQ). The drug was given once a
day. The dosage was adjusted according to the age: 3
tablets per day if age was more than 16 years; 2 tablets
per day if age was between 11 and 16 years and 1.5
tablets if the age was between 6 and 11 years.
Data collection
After inclusion, patients were followed at day 0 (day of
inclusion), 1, 2, 3, 7, 14, 21 and 28. A random sub-
sample of study participants was followed up to day 35
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and day 42 to assess the long term protective effect of
each drug after curative doses. A clinical and biological
assessment was performed for all patients. The 2003
WHO’s protocol for antimalarial drug efficacy evaluation
was used [10].
Clinical assessment
A clinical examination and an interview were performed
before the inclusion. After inclusion and first dose ad-
ministration, all patients were examined during the first
4 days. At each follow up visit, a clinical examination
and interview to evaluate the patient’s clinical conditions
as well as the occurrence of adverse events were done.
Patients were seen by the medical team at any time if
they did not feel well.
Biological assessment
A blood sample was collected for thick and thin smears
for all study patients. Both tests were used to determine
the parasite density and the plasmodium species at the
day 0, 1, 2, 3, 7, 14, 21, and 28. Both tests were repeated
at day 35, 42 and other days of follow up to evaluate
parasite clearance times.
To distinguish recrudescence form new infection,
blood was collected on filter paper at day 0 and at day of
parasite reappearance.
The haemoglobin level was determined at day 0 and day
7 using Sysmex XS 1000i automate. Creatinine, urea, bili-
rubin, aspartate amino-transferase (ASAT) and alanine-
aminotransferase (ALAT) were also examined at day 0
and day 7 using automate A15 of Biosystems laboratories.
Laboratory methods
Thick and thin smear
Finger prick blood was used to collect blood samples.
Thick and thin smears were stained with Giemsa. The
parasite density was evaluated by counting the number
of asexual parasites per 200 white blood cells and calcu-
lated per μl: number of parasites × 8000/200 assuming a
white blood cell count of 8000 cells per μl. Thick and
thin smears were negative after 100 field microscopics
reading.
Haematological and biochemical assessment
Haematological and biochemical parameters were per-
formed at enrolment and day 7 to determine the
haemoglobin level, the concentration of urea, creatin-
ine, bilirubine, asparta-amino-transferase (AST) and
alanine-amino-transferase (ALAT).
Polymerase chain reaction (PCR)
The PCR was used to distinguish recrudescence from
new infection in case of treatment failure. Nested PCR
was conducted to compare the genetic polymorphism of
P falciparum genes (Merozoïte Surface Protein): MSP1
and MSP2 [11]. Recrudescence was defined as at least
one identical allele for each of the two markers in the
pre-treatment and post-treatment samples. New infec-
tions were diagnosed when all alleles for at least one of
the markers differed between the two samples.
Definition of early and late parasitological failure
Early treatment failure
This was defined as a development of danger signs or
severe malaria on days 1–3 in the presence of parasit-
aemia, a patient with parasitaemia on day 2 higher than
the day 0 count irrespective of axillary temperature;
parasitaemia on day 3 with axillary temperature ≥ 37.5°C
and parasitaemia on day 3 that is ≥ 25% of count on
day 0.
Late parasitological failure
This was defined as a presence of parasitaemia on any day
from day 7 to day 28 and axillary temperature < 37.5°C,
without previously meeting any of the criteria of early
treatment failure or late clinical failure.
Adequate clinical and parasitological response (ACPR)
The ACPR was defined as an absence of parasitaemia on
day 28 irrespective of axillary temperature without previ-
ously meeting any of the criteria of early treatment fail-
ure, late clinical failure or late parasitological failure [2].
Statistical methods
Based on an expected therapeutic effect of AL not
low than 95% [12] assuming a non-inferiority margin
of 7% (two side) and power at 80%, using a 95%
confidence level and accounting for 10% of lost to follow
up, sample size for each study arm was evaluated at 155
participants.
Data collected were entered into Excel software and the
analysis was done with Stata IC 12 software. Intention to
treat and per protocol analysis were performed.
The intention to treat included all randomized
subjects who took at last one full dose and had one
post-baseline efficacy without major protocol deviation.
The per protocol analysis include all subjects who re-
ceived the three dose and had no major protocol
deviation.
Data were analysed by estimation of difference in
proportion according to a 95% confidence interval.
Groups were compared using Chi Square test or Fisher
exact test for categorical variables and Student’s t-test
for continuous variables when these tests were applic-
able. Otherwise, non- parametric tests (Mann–Whitney,
Kruskall-Wallis) were used.
The cumulative incidence of failure rate was calculated
in each group and compared using Kaplan Meier
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method. Changes in biological parameters from day 0 to
day 7 were calculated and compared between treatment
arms using Bonferroni test.
Statistical significance for all tests was set at 0.05
(p value < 0.05 two side).
Ethical considerations
This study was conducted according to the Declaration
of Helsinki and existing national legal and regulatory re-
quirements. The protocol was reviewed and approved by
the Senegalese National Ethical Committee (Conseil
National d’Ethique et de Recherche en Santé). Written
informed consent was obtained from each participant or
their parent or guardian for particiapants with an age
below 18 years. The study was registered at the Pan




Overall, 1495 febrile patients were screened for malaria.
947 of them were positive for Plasmodium falciparum
malaria. For positives subjects, 534 of them meet the in-
clusion criteria: 180 in the ASAQ arm, 178 in the AL arm
and 176 in the DHAPQ arm. Withdrawal of consent was
noted in 2 patients in the ASAQ arm, 1 patient in the AL
arm and 3 patients in the DHAPQ arm. During the follow
up, 7 patients in ASAQ group, 1 patient in AL group and
8 patients in DHAPQ group were lost to follow up. Proto-
col violations were observed in 2 subjects in ASAQ group,
4 patients in AL group and 3 subjects in DHAPQ group.
At the end of the study, 534 patients were included in ITT
analysis and 503 patients in PP analysis at day 28. The PP
analysis at day 35 and day 42 concerned respectively 470
and 411 patients (Figure 1).
Screening (n=1495)
Not meeting inclusion criteria (n=64)
Declined to participate (n=255)
Other reasons (n=94 )
Analysed at day 28 
ITT analysis at day 28 (n=180)
PP analysis at day 28 (n=169)
Analysed at day 35 (n=160)
Analysed at day 42 (n=136)












Analysed at day 28 
ITT analysis at day 28 (n=176)
PP analysis at day 28 (n=162)
Analysed at day 35 (n=148)
Analysed at day 42 (n=134)
Artemether-Lumefantrine: AL 
(n=178)
Lost to follow-up (n=1)
Withdraw consent (n=1)
Protocol violation (n=4)
Follow up at D 28 (n= 169)
Follow up at D 35 (n=160)
Follow up at D 42 (n=136)
Follow up at D 28 (n= 172)
Follow up at D 35 (n=162)
Follow up at D 42 (n=141)
Follow up at D 28 (n= 162)
Follow up at D 35 (n=148)
Follow up at D 42 (n=134)
FOLLOW-UP
ANALYSIS
Analysed at day 28 
ITT analysis at day 28 (n=178)
PP analysis at day 28 (n=172)
Analysed at day 35 (n=162)
Analysed at day 42 (n=141)
Figure 1 Trial profile.
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Baseline characteristics of subjects at inclusion in the
three treatment groups
At inclusion, the three groups were comparable in term
of age, weight, sex ratio, temperature and parasitemia.
The median age was 14 years in the ASAQ and DHAPQ
groups and 13 years in the AL group. The sex ratio was
1.85, 1.17 and 1.41 respectively in the ASAQ, AL and
DHAPQ arm. The mean weight in each group was
38.9 ± 18 kg, 37.5 ± 20 kg and 42.4 ± 19 kg for ASAQ,
AL and DHAPQ, significantly higher in the last
group. The mean temperature was almost similar in
the three treatment groups. The proportion of subjects with
fever on admission was 75% (135/180), 75.8% (135/178)
and 76.14% (134/176) respectively in ASAQ, AL and
DHAPQ group.
The median parasitemia was 13132.5 trophozoites/μl
in ASAQ arm, 26192.5 trophozoites/μl in AL arm and
21347.5 trophozoites/μl in DHAPQ arm (Table 1).
Biological characteristics of patients at inclusion
No significant difference was observed in the mean level
of haemoglobin, creatinine, bilirubin and liver enzymes
such as ASAT and ALAT in the three groups treatment
(Table 1).
Therapeutic efficacy
There were no early treatment failures and cure rates,
both PCR uncorrected and corrected, for all three treat-
ment groups were higher than 95% by ITT and PP ana-
lysis, with no significant differences observed between
the groups (Table 2).
The Kaplan Meier survival analysis resulted in a very
similar cumulative incidence failure rate at day 28 in all
three groups (log rank test, p = 0.83) (Figure 2).
A very low rate of late parasitological failures were
detected (Table 2).
There were 88% (n = 470) and 77% (n = 411) of all
patients seen at day 35 and day 42 respectively. Again
very good cure rates were observed with no significant
difference detected between the groups (Table 3).
Fever and parasite clearance
Fever clearance was similar in the three treatment
groups. At inclusion, the proportion of subjects with
fever was 75% (135/180), 75.8% (135/178) and 76.14%
(134/176) respectively in ASAQ, AL and DHAPQ group.
The difference was not significative at inclusion between
the groups (p = 0.96). After first dose administration,
3.8% (7/180) patients in ASAQ group and 3.4% (6/176)
patients in DHAPQ group were found with fever. The
proportion of patients with fever was more important in
the AL group 8.4% (15/178) with no significant differ-
ence (p = 0.06). The fever clearance was noted at day 2
after the first dose treatment.
The three treatments showed rapid parasite clearance
time. The parasitemia at inclusion was 13132.5 tropho-
zoites/μl in ASAQ group, 26192.5 trophozoites/μl in AL
group and 21347.5 trophozoites/μl in DHAPQ group. At
day 1 after first dose administration, the parasitemia
decreased to 1139.8 trophozoites/μl in ASAQ group,
583.03 trophozoites/μl in AL group and 277.73 trophozo-
ites/μl in DHAPQ group. The proportion of patients
remaining parasitemic at day 1 was 75% (135/180), 66.8%
Table 1 Baseline characteristics of subjects at the inclusion in the three treatment groups
Parameters DHAPQ (N = 176) AL (N = 178) ASAQ (N = 180)
Age (median ± SD, years) 14 ± 10 13 ± 12 14 ± 12
Sex ratio (F/M) 1.41 1.17 1.85
Weight (mean ± SD, Kg) 42.4 ± 19 37.5 ± 20 38.9 ± 18
Temperature (mean ± SD) 38.1 ± 1.1 38 ± 1.08 38 ± 2
Patients with fever 76.14% 75.8% 75%
Parasitemia (median ± trophozoites/μL) 21347.5 26192.5 13132.5
Hb mean (g/dl) 11.88 11.89 11.48
Anemia (Hb < 11 g/dl) (%) 24.43 22.47 29.44
ALAT (UI/L, mean ± SD) 19 21 20.76
ASAT (UI/L, mean ± SD) 34.37 33.52 32.17
Patients with ALAT < 40 UI/L (%) 89.77 88.20 84.44
Patients with ASAT < 40 UI/L (%) 80.68 83.15 88.20
Mean bilirubin 1.3 1.5 0.81
Patients with normal level of bilirubin (0.23 – 1 mg/dl) 77.27 79.78 79.44
Mean creatinine (mg/l) 8.15 8.75 7.9
Patients with normal level of creatinine (6 – 14 mg/l) (%) 77.27 80.34 93.33
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(119/178) and 48.8% (86/176) respectively in ASAQ, AL
and DHAPQ group (p < 10-3). At day 2, this proportion
was 3.3% (6/180), 6.7% (12/178) and 2.3% (4/176). The
difference was not significative at day 2 after first dose
administration (p = 0.08) between the three treatments
groups. Complete parasite clearance was obtained at day 3
after inclusion.
Clinical and biological tolerance
The three treatments were well tolerated during the
study period. No serious adverse event was observed. No
patient died during the study period and no signs of
neurotoxicity were observed. The main adverse events
were minor and they were represented by vomiting,
abdominal pain, herpes labialis, dizziness and diarrhea.















% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Intention to
treat analysis
Early treatment failure 00 00 00 00 00 00
NA 6/176 (3.41%) 2/178 (1.12%) 4/180 (2.22%) 6/176 (3.41%) 2/178 (1.12%) 4/180 (2.22%)
Late parasitological
failure














[89.3-99.9] [87.3-99.9] [88.8-99.9] [88.7-99.9] [86.8-99.9] [88.4-99.9]












% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Early treatment
failure
00 00 00 00 00 00
Late parasitological
failure
1/162 (0.62%) 1/172 (0.58%) 1/169 (0.59%) 00 00 1/169 (0.59%)
ACPR 161/162 (99.38%) 171/172 (99.42%) 168/169 (99.41) 0.99 162/162 (100%) 172/172 (100%) 168/169 (99.41) 0.37
[85.7-99.9] [86.1-99.9] [86–99.9] [85.2-99.9] [85.6-99.9] [86–99.9]
NA: Not Applicable, ACPR: Adequate Clinical and Parasitological Response.
Figure 2 Kaplan Meier survival estimates of efficacy in three treatment groups in ITT analysis at day 28.
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Abdominal pains were more frequent in ASAQ group
16.66% (30/180) versus 10.79% (19/176) in DHAPQ
group and 7.86% (14/178) in AL group (p = 0.31).
Vomiting was more frequent in DHAPQ group 5.68%
(10/176) compared to AL group 2.45% (4/178) and
ASAQ group 1.66% (3/180) (p = 0.06). Labial herpes was
more frequent in AL group 3.37% (6/178).
Biological tolerance was good during the three treat-
ments. No major biological disorder was observed.
The mean of haemoglobin was lower at day 7 in the
three treatments groups compared to hemoglobin mean
at day 0. The difference between the three treatment
groups at day 7 was not significative (p = 0.19). Anemia
was most frequent at day 7 in three groups compared to
inclusion. This was more important in AL group
(70.79%). The difference was not significative between
the three groups (p = 0.31).
An improvement of liver function was observed
between day 0 and day 7. The number of patients with
normal transaminase was higher at day 7 compared to
the enrollment.
Regarding the mean of creatinine, no significant vari-
ation was observed between day 0 and day 7 in the three
treatment arms. A significant decrease of bilirubin level
was noted at day 7 in the three treatment arms
(Table 4).
At the pair analysis, the haemoglobin mean decreased
from day 0 to day 7 with no statistical difference
between AL and DHAPQ treatment groups (p = 1).
From day 0 to day 7, this mean decreased to 1.1 g/dl
versus 0.52 g/dl respectively in AL and ASAQ groups.
Haemoglobin level decreased to 1.4 g/dl from day 0 to
day 7 in the DHAPQ group versus 0.52 g/dl in the
ASAQ group (p < 0.001). Overall the ALAT mean
decreased from day 0 to day 7 in the three treatments
groups. No statistical difference was noted between
ASAQ (2.57 UI/L) and AL (3.65 UI/L) groups (p = 1)
and between AL (16.2 UI/L) and DHAPQ (2.58 UI/L)
groups (p = 1). From day 0 to day 7, the mean ALAT
decreased to 3.65 UI/L in AL group versus 2.58 UI/L in
DHAPQ group (p = 0.48). The mean ASAT decreased to
6.4 UI/L in ASAQ group versus 9.5 UI/L in AL group
from day 0 to day 7 (p = 0.54). Same tendency was noted
in DHAPQ (8.7 UI/L) and AL (9.5 UI/L) groups from
day 0 to day 7 (p = 1). There was no significant differ-
ence in ASAT level from day 0 to day 7 in ASAQ and
DHAPQ arms (p = 0.94). From day 0 to day 7, the mean
production of creatinin decreased to 0.18 mg/l in ASAQ
group versus 0.41 mg/l in DHAPQ group (p = 1). In AL
group this mean decreased to 1.39 mg/l from day 0 to
day 7 versus 0.18 mg/l in ASAQ group (p = 0.77). Re-
garding AL group versus DHAPQ group, the mean crea-
tinin decreased respectively to 1.39 mg/L and 0.41 mg/l
from day 0 to day 7 (p = 1).
Overall, the mean bilirubin decreased from day 0 to
day respectively to 0.17 mg/dl, 0.91 mg/dl and 0.78 mg/dl
in ASAQ, AL and DHAPQ group. The difference was
significative between ASAQ and AL groups and between















% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Day 35
Late parasitological failure 1/148 1/162 2/160 00 00 1/160 (0.625%)
(0.67%) (0.62%) (1.25%)
ACPR 147/148 161/162 158/160 0.79 148/148 162/162 159/160 0.37
(99.33%) (99.38%) (98.75%) (100%) (100%) (99.375%)













% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Late parasitological failure 1/134 4/141 4/136 00 00 1/136
(0.75%) (2.84%) (3%) (0.73%)
ACPR 133/134 137/141 132/136 0.38 134/134 141/141 135/136 0.36
(99.25%) (97.16%) (97%) (100%) (100%) (99.27)
[84.4-99.9] [86.6-99.9] [87.1-99.9] [83.7-99.9] [84.2-99.9] [84.5-99.9]
ACPR, Adequate Clinical and Parasitological Response; NA, Not Applicable.
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ASAQ and DHAPQ groups (p < 10-3). There was not sig-
nificative between AL and DHAPQ groups (p = 0.46)
(Table 5).
Overall, the pair analysis showed an improvement of
liver and kidney function from day 0 and day 7.
Discussion
This study was undertaken to assess the efficacy and the
safety of the three artemisinin combination therapies
commonly used in Senegal. The study showed that AL,
DHAPQ and ASAQ are highly effective for the treat-
ment of uncomplicated Plasmodium falciparum malaria.
These findings are consistent with results reported from
other trials. In Senegal, Tine et al. in 2010 reported a
cure rate of 96.7% at day 28 for AL in a clinical trial
assessing the efficacy and tolerability of new formulation
of Artesunate-Mefloquine [13]. Faye et al. obtained a
cure rate of 97% for AL in a multicentric study (Senegal
and Ivory Coast) from September 2007 to November
2008 [14].
Menan et al. from, in a multicentric study including
Cameroon, Ivory Coast and Senegal September 2008 to
February 2009, obtained a PCR adjusted ACPR at day 28
of 99% in AL group [15]. Makanga et al. obtained a
Table 4 Patients’ biological profile at day 7 in the three treatment groups
Parameters DHAPQ (N = 176) AL (N = 178) ASAQ (N = 180) p value
Hb mean (g/dl) 10.74 10.75 10.96 0.19
Anemia (Hb < 11 g/dl) (%) 63.64 70.79 69.44 0.31
ALAT (UI/L, mean ± SD) 16.42 17.34 18.19 0.58
ASAT (UI/L, mean ± SD) 25.6 23.9 25.8 0.09
Patients with ALAT < 40 UI/L (%) 90.34 93.82 91.67 0.47
Patients with ASAT < 40 UI/L (%) 90.91 95.51 98.89 0.002
Mean bilirubin (mg/dl) 0.56 0.58 0.64 0.02
Patients with normal level of bilirubin (0.23 – 1 mg/dl) (%) 96.59 96.07 93.89 0.42
Mean creatinine (mg/l) 7.74 7.31 7.72 0.93
Patients with normal level of creatinine (6 – 14 mg/l) (%) 96.59 96.07 100 0.03
Table 5 Biological parameter changes from day 0 to day 7 by treatment arms
Treatment Group Point estimate changes of biological parameters from day 0 to day 7 (95% IC) Mean difference p value
Haemoglobin (g/dl)
ASAQ 0.52 ± 0.11 (0.28 – 0.75) ASAQ ≠ AL: 0.62 <10-3
AL 1.1 ± 0.09 (0.96 – 1.32) ASAQ ≠ DHAPQ: 0.62 <10-3
DHAPQ 1.1 ± 0.08 (0.98 – 1.31) AL ≠ DHAPQ: 0.001 1
ALAT (UI/L)
ASAQ 2.57 ± 1.86 (−1.1 – 6.2) ASAQ ≠ AL: 1.08 1
AL 3.65 ± 1.2 (1.2 – 6.1) ASAQ ≠ DHAPQ: 0.008 1
DHAPQ 2.58 ± 1.5 (−0.3 – 5.5) AL ≠ DHAPQ: -1.07 1
ASAT (UI/L)
ASAQ 6.37 ± 0.4 (5.4 – 7.3) ASAQ ≠ AL: 3.17 0.54
AL 9.55 ± 1.8 (5.9 – 13.1) ASAQ ≠ DHAPQ: 2.38 0.94
DHAPQ 8.75 ± 2.2 (4.3 – 13.2) AL ≠ DHAPQ: -0.79 1
Creatinin (6–14 mg/l)
ASAQ 0.18 ± 0.7 (−1.2 – 1.6) ASAQ ≠ AL: 1.21 0.77
AL 1.39 ± 0.5 (0.3 – 2.4) ASAQ ≠ DHAPQ: 0.22 1
DHAPQ 0.41 ± 0.9 (−1.4 – 2.3) AL ≠ DHAPQ: -0.98 1
Bilirubin (0.23 - 1 mg/dl)
ASAQ 0.17 ± 0.03 (0.1 – 0.23) ASAQ ≠ AL: 0.74 <10-3
AL 0.91 ± 0.07 (0.7 – 1.06) ASAQ ≠ DHAPQ: 0.61 <10-3
DHAPQ 0.78 ± 0.07 (0.6 – 0.9) AL ≠ DHAPQ: -0.12 0.46
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therapeutic efficacy for AL above 95% for the treatment
of uncomplicated malaria [16]. Regarding ASAQ com-
bination, Faye et al. in 2008 in a multicentric study
(Senegal, Cameroon and Ivory Coast) evaluating the
non-inferiority of the new paediatric formulation of
Artesunate/Amodiaquine versus Artemether/Lumefantrine
for malaria treatment reported a therapeutic efficacy at
day 28 at 98.7% when ASAQ was given to children under
5 years of age [17].
Ndiaye et al., in randomized trial assessing the efficacy
of a fixed dose of ASAQ combination from March to
December 2006, showed an adjusted ACPR at day 28
more than 98% [18].
NDounga et al. in 2005 in Brazaville, obtained 94.4%
of cure rate at day 28 when ASAQ combination was
given to children [19]. Zwang et al. in a multi-centre
analysis of the efficacy of ASAQ combination showed
good ACPR after PCR correction. For DHAPQ combin-
ation similar results were obtained [20]. Yavo et al. from
November 2006 to May 2008 in multi-centre study
assessing the efficacy of DHAPQ obtained 99.5% of
ACPR after PCR correction [21].
In Thaïland, Ashley et al. between July 2002 and April
2003 showed a cure rate of 98.3% in the DHAPQ group
[22]. Many studies have reported good efficacy of
DHAPQ combination for malaria treatment [23-25]. The
three antimalarial drugs remained highly effective at
days 35 and 42. Compared to others drugs, DHAPQ has
good cure rate more than 98%. This result was demon-
strated by Grande et al. and by Zwang et al [26,27].
After the administration of the three ACT used in
this study, it resulted in a rapid decrease of fever and
parasite. The fever and parasite clearance was ob-
tained respectively at day 2 and day 3 after the initial
dose. Similar results were obtained by Tine et al.,
Faye et al. in Senegal and Gbotosho et al. in Nigeria
[13,14,28].
The three antimalarial treatments were well tolerated
with a similar safety profile. Indeed, no serious adverse
event was noted. The main adverse events were minor
and they were represented by vomiting, abdominal pain,
herpes labialis, dizziness and diarrhea. However abdom-
inal pains were more frequent in patients treated with
ASAQ, vomiting was more frequent in patients treated
with DHAPQ and labial herpes was more frequent in
AL group. Previous study demonstrated that these ACTs
are well tolerated [13-15].
No major biological disorder was observed in our
study. Anemia was most frequent at day 7 in three
groups compared at day 0. Similar results were noted by
others study. Olliaro et al. observed a decrease of
haemoglobin level at day 7 after malaria treatment [29].
Same trends were noted by Price et al. and by Zwang
et al. [30,31].
In Senegal, notification of adverse events has been a
great challenge for the National Malaria Control
Programme although a pharmacovigilance system to
monitor ACT drug related adverse events has been
established since 2006 [9]. This study provided scientific
evidence that can contribute to supplement existing data
regarding on ACT safety in Senegal.
Study limitation
AL was not given with fat diet in our study. This could
explain the decrease of the efficacy. However many stud-
ies have reported good efficacy when AL was given with
fat. Thus Ashley et al. in pharmacokinetic study of AL in
2002 showed that the high-fat allowed having a good
absorption of the drug. This had resulted in an increase
of therapeutic efficacy [32].
Mayxay M et al., in the efficacy study of AL in Southern
Laos between June and November from 2008–2010
showed good efficacy of AL with a cure rate more than
95% when AL was given with fatty food [33].
Many studies reported an increase of haemoglobin
level from day 7 to 28 after treatment with ACT [20,31].
In this study haemoglobin level was assessed at day 0
and day 7. Additional haemoglobin dosages at day 14, 21
and 28 would provide more information on haemoglo-
bine changes after treatment with ACTs; theses assess-
ments were not done in the study.
Conclusions
DHAPQ, AL and ASAQ are highly effective and safe
antimalarial drugs. These ACTs remain useful antima-
larial interventions for effective malaria control. It is
however important to continue to monitor their efficacy
in the context of scaling up of ACTs in Senegal.
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